PRNewswire/ -- Nu Skin Enterprises, Inc. (NSE) today announced the addition of Laura Nathanson to NSE's board of directors. Nathanson is currently Disney Advertising Sales executive vice president of revenue and operations...
DURHAM, N.C., May 30, 2019 /PRNewswire/ -- Emergo Therapeutics, which continues to accelerate its lead candidate norketotifen through Phase 2 studies, has added another seasoned executive to its Board of Directors. Jack Bailey, President, US Pharmaceuticals at GlaxoSmithKline, joined the Board on May 17, 2019. Moise Khayrallah, PhD, CEO and Chairman of the Board, Meg Powell, PharmD, Co-Founder of Target Pharma Solutions, and Bobby Helmedag, Managing Director, Rex Health Ventures, will continue to serve with Bailey...
PALO ALTO, Calif., April 15, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for serious rare and ultra-rare diseases, announced today the appointment of Amit K. Sachdev, JD to its Board of Directors...
NORTH HOLLYWOOD, Calif., April 8, 2019 /PRNewswire/ -- ConsejoSano, a multicultural patient engagement platform for payers, providers and health systems, announced today that Dr. Molly J. Coye has joined ConsejoSano's board of directors...
March 21, 2019 /PRNewswire/ -- Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designing precise cancer therapeutics by targeting essential kinases, announced today the appointment of Magda Marquet , Ph.D., to its Board of Directors...
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc.(NASDAQ:PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ System, today announced the appointment of Mitchell Levinson to its board of directors. In connection with his appointment to the board, Mr. Levinson will also serve as a member of the audit committee...
IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Michael H. Carrel has been appointed to the Axonics board of directors, effective immediately...
( BUSINESS WIRE )-- Henry Schein, Inc. (Nasdaq: HSIC) and Vets First Choice today announced their designees who will comprise the 11-member board of directors for Covetrus, the new standalone public company that will result from the planned spin-off of the Henry Schein Animal Health business and the subsequent merger with Vets First Choice...
NASHVILLE, Tenn., /PRNewswire/ -- OneOncology announced the election of former U.S. Senate Majority Leader, Bill Frist to its board of directors...
SAN FRANCISCO, /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it has appointed Karin Eastham as an independent ...
Dr. Dillon currently serves on the Board of Directors of the Wistar Institute and is an advisor to the DMAX Foundation which is focused on mental health ...
Invacare Corporation (NYSE: IVC) today announced the appointment of Diana S. Ferguson, to its Board of Directors , effective July 19, 2018...
A tangled web has been woven at Michigan-based Rockwell Medical. The board of directors has fired the chief executive officer and chief financial ...
BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Alpna Seth, Ph.D. has been appointed to the company's Board of Directors . Dr. Seth has more than 20 years of global experience in the healthcare and biotechnology/pharmaceutical industry, including ...
BEDFORD, Mass., Jan. 17, 2018 /PRNewswire/ -- Homology Medicines, a genetic medicines company, announced today the appointment of Matthew R. Patterson, Co-Founder, President and Chief Executive Officer of Audentes Therapeutics, to Homology's Board of Directors . Mr. Patterson is a biotech ...
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics (NASDAQ:GBT) today announced the appointment of Wendy L. Yarno to the company's board of directors . Ms. Yarno has more than 25 years of experience in the biopharmaceutical industry, including ...
Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors - read this article along with other careers information, tips and ...
Spruce Biosciences Appoints Camilla V. Simpson to Board of Directors - read this article along with other careers information, tips and advice on ...
Shares of Teva Pharmaceuticals are up more than 5 percent this morning after Israeli media reported billionaire businessman Len Blavatnik is considering taking a large stock position in the pharma giant. Citing multiple Israeli media outlets, Reuters reported Blavatnik “has been examining a large share purchase in Teva.” According to reports, Blavatnik could invest up to $3 billion in Teva...
Sigilon Therapeutics Appoints Eric Shaff to Board of Directors - read this article along with other careers information, tips and advice on BioSpace...
Leading Pharmaceutical Executive Dr. Robert Karr Joins Verseon's Board of Directors - read this article along with other careers information, tips and ...
The former CEO of Ariad Pharmaceuticals Inc., who spent the last year shaping up the Cambridge-based drug company for its $5.2 acquisition earlier this year, was just named to the board of a new biotech last week. There, as the newest board member of New Jersey-based The Medicines Company, Paris Panayiotopoulos joins a familiar face: Alex Denner, former chairman of Ariad (Nasdaq: ARIA)...
Kite Pharma, Inc. today announced that Owen N. Witte, M.D., the founding director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California Los Angeles and a renowned cancer researcher, has been appointed to its Board of Directors...
Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven"), a privately-held, clinical stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, announced today that it has completed the second tranche of its previously disclosed $80 million private financing...